ES2139904T3 - Sistema de suministro celular de ciclodextrina para oligonucleotidos. - Google Patents

Sistema de suministro celular de ciclodextrina para oligonucleotidos.

Info

Publication number
ES2139904T3
ES2139904T3 ES95922923T ES95922923T ES2139904T3 ES 2139904 T3 ES2139904 T3 ES 2139904T3 ES 95922923 T ES95922923 T ES 95922923T ES 95922923 T ES95922923 T ES 95922923T ES 2139904 T3 ES2139904 T3 ES 2139904T3
Authority
ES
Spain
Prior art keywords
cyclodextrin
cell
oligonucleotides
oligonucleotide
supply system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95922923T
Other languages
English (en)
Inventor
Sudhir Agrawal
Qiuyan Zhao
Ivan Habus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ES2139904T3 publication Critical patent/ES2139904T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE MUESTRA UNA COMPOSICION INCLUYE UN OLIGONUCLEOTIDO COMPLEMENTADO POR UNA CICLODEXTRINA. EL OLIGONUCLEOTIDO PUEDE ASOCIARSE DE FORMA NO COVALENTE CON LA CICLODEXTRINA. DE FORMA ALTERNATIVA EL OLIGONUCLEOTIDO PUEDE COMPLEMENTARSE COVALENTEMENTE CON ADAMANTANO QUE SE ASOCIA DE FORMA NO COVALENTE CON LA CICLODEXTRINA. TAMBIEN SE MUESTRAN METODOS PARA MEJORAR LA TOMA CELULAR Y LA CONCENTRACION INTRACELULAR DE OLIGONUCLEOTIDOS, METODOS PARA AUMENTAR LA SOLUBILIDAD DE UN OLIGONUCLEOTIDO EN UNA CELULA, Y METODOS PARA TRATAR UNA CELULA INFECTADA VIRALMENTE O PARA PREVENIR LA INFECCION VIRAL.
ES95922923T 1994-06-01 1995-06-01 Sistema de suministro celular de ciclodextrina para oligonucleotidos. Expired - Lifetime ES2139904T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25207294A 1994-06-01 1994-06-01

Publications (1)

Publication Number Publication Date
ES2139904T3 true ES2139904T3 (es) 2000-02-16

Family

ID=22954476

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95922923T Expired - Lifetime ES2139904T3 (es) 1994-06-01 1995-06-01 Sistema de suministro celular de ciclodextrina para oligonucleotidos.

Country Status (12)

Country Link
US (3) US5691316A (es)
EP (1) EP0762898B1 (es)
JP (1) JPH10501237A (es)
CN (1) CN1158088A (es)
AT (1) ATE186647T1 (es)
AU (1) AU2764395A (es)
CA (1) CA2191777A1 (es)
DE (1) DE69513395T2 (es)
DK (1) DK0762898T3 (es)
ES (1) ES2139904T3 (es)
GR (1) GR3032355T3 (es)
WO (1) WO1995032739A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099959A1 (en) * 1995-04-12 2003-05-29 Kandimalla Ekambar R. Cooperative oligonucleotides
US6667293B1 (en) * 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
US6573101B1 (en) * 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
US6716589B2 (en) 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
AU2002365077A1 (en) * 2001-09-19 2003-06-30 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP2325193A3 (en) * 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
CA2428740A1 (en) * 2002-05-20 2003-11-20 Bayer Corporation Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf)
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CA2501132A1 (en) * 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
EP1605978B1 (en) 2003-03-07 2010-09-01 Alnylam Pharmaceuticals Inc. Therapeutic compositions
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
AU2004232964B2 (en) 2003-04-17 2011-09-22 Alnylam Pharmaceuticals, Inc. Protected monomers
WO2004094595A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
AU2004255557B2 (en) 2003-06-09 2010-06-10 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
SG124419A1 (en) * 2005-02-03 2006-08-30 Agency Science Tech & Res Polycations capable of forming complexes with nucleic acids
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
CA2732229C (en) * 2008-07-25 2023-10-17 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US20100056612A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Molecular entities for binding, stabilization and cellular delivery of charged molecules
US20110256592A1 (en) * 2008-12-12 2011-10-20 Eurogentec S.A Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions
WO2010088282A1 (en) * 2009-01-30 2010-08-05 Rgo Biosciences Llc Nucleic acid binding assays
MX2012005987A (es) * 2009-11-23 2012-06-25 Cerulean Pharma Inc Polimeros a base de ciclodextrina para administracion terapeutica.
US20110218156A1 (en) * 2010-02-04 2011-09-08 Alexander Chucholowski Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
GB201216387D0 (en) 2012-09-13 2012-10-31 Ge Healthcare Uk Ltd Solid matrix for one step nucleic acid amplification
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
KR101465365B1 (ko) * 2013-10-15 2014-11-25 성균관대학교산학협력단 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법
IL291323B2 (en) 2016-07-15 2023-09-01 Am Chemicals Llc Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis
US20190177800A1 (en) * 2017-12-08 2019-06-13 10X Genomics, Inc. Methods and compositions for labeling cells
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP3802819A1 (en) * 2018-05-30 2021-04-14 AXOLABS GmbH Method for detecting oligonucleotide conjugates
CN114874358B (zh) * 2022-04-11 2023-05-02 上海师范大学 一种多核铈纳米材料的合成方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
PT91088B (pt) * 1988-07-07 1995-01-31 Univ Pennsylvania Processo de preparacao de composicoes a base de alfa-,beta- ou gama- -cilcodextrinas
WO1991002040A1 (en) * 1989-08-04 1991-02-21 Kosak Kenneth M Cyclodextrin labels for nucleic acid and biochemical analysis
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
JPH05170650A (ja) * 1991-12-19 1993-07-09 Sanyo Kokusaku Pulp Co Ltd 医薬組成物およびその製造方法
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil

Also Published As

Publication number Publication date
DE69513395T2 (de) 2000-07-27
DE69513395D1 (de) 1999-12-23
GR3032355T3 (en) 2000-04-27
WO1995032739A1 (en) 1995-12-07
EP0762898B1 (en) 1999-11-17
US5616565A (en) 1997-04-01
US5691316A (en) 1997-11-25
US5605890A (en) 1997-02-25
CN1158088A (zh) 1997-08-27
EP0762898A1 (en) 1997-03-19
ATE186647T1 (de) 1999-12-15
JPH10501237A (ja) 1998-02-03
CA2191777A1 (en) 1995-12-07
DK0762898T3 (da) 2000-04-25
AU2764395A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ES2139904T3 (es) Sistema de suministro celular de ciclodextrina para oligonucleotidos.
DK1143967T3 (da) Anticonvulsive derivater egnede til behandling af Hortons hovedpine
ATE332918T1 (de) Neoglycoproteine
NO20014662D0 (no) Fremgangsmåter og preparater for behandling av faste tumorer
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE60134147D1 (de) Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
MY138883A (en) Use of asiatic acid for treatment of cencer
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
NZ521988A (en) Polyamide nucleic acid derivatives, agents and methods for producing them
NO20000021L (no) Fremgangsmåte og anordning for å hindre oppblomstring av mikroorganismer i et vandig system
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
MY134896A (en) Therapeutic agent for hepatitis
BR0012735A (pt) Preparação solida, e, processo para produzir preparações
ATE291586T1 (de) Humanes antibiotisches protein
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
MY118864A (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer
DE50007818D1 (de) Komplexierung von rns, insbesondere von ribozymen, mit polyethyleniminen zu deren stabilisierung und zellulären einschleusung
PT1054680E (pt) Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei
GB0400264D0 (en) Complexes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 762898

Country of ref document: ES